Matrix metalloproteinases in kidney disease progression and repair: A case of flipping the coin

被引：45
作者：
Ronco, Pierre
Lelongt, Brigitte
Piedagnel, Remi
Chatziantoniou, Christos
机构：
[1] Hop Tenon, INSERM, Unit 702, F-75020 Paris, France
[2] Univ Paris 06, Paris, France
来源：
SEMINARS IN NEPHROLOGY | 2007年 / 27卷 / 03期
关键词：
MMP inhibitors; extracellular matrix; hypertensive nephrosclerosis; Alport syndrome; crescentic glomerulonephritis;
D O I：
10.1016/j.semnephrol.2007.02.006
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Matrix metalloproteinases (MMPs) have pleiotropic enzymatic actions that go far beyond degradation of extracellular matrix. Both the multiplicity of their targets and the complexity of their regulation account for a variety of biological effects. In renal diseases, MMP effects may be different and/or opposite during the different phases of the pathology evolution. The major challenge with future therapeutic interventions using MMP inhibitors remains how to accomplish temporal and spatial control of their activity without flipping the coin.
引用
收藏
页码：352 / 362
页数：11
相关论文
共 45 条
[1]   Gelatinase B (MMP-9) is not essential in the normal kidney and does not influence progression of renal disease in a mouse model of Alport syndrome [J].
Andrews, KL ;
Betsuyaku, T ;
Rogers, S ;
Shipley, JM ;
Senior, RM ;
Miner, JH .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 157 (01) :303-311
[2]   Tissue inhibitor of metalloproteinase-2 stimulates mesenchymal growth and regulates epithelial branching during morphogenesis of the rat metanephros [J].
Barasch, J ;
Yang, J ;
Qiao, JZ ;
Tempst, P ;
Erdjument-Bromage, H ;
Leung, W ;
Oliver, JA .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (09) :1299-1307
[3]   Integrin-linked kinase in renal disease: connecting cell-matrix interaction to the cytoskeleton [J].
Blattner, SM ;
Kretzler, M .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2005, 14 (04) :404-410
[4]   Regression of renal vascular and glomerular fibrosis: Role of angiotensin II receptor antagonism and matrix metalloproteinases [J].
Boffa, JJ ;
Lu, Y ;
Placier, S ;
Stefanski, A ;
Dussaule, JC ;
Chatziantoniou, C .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (05) :1132-1144
[5]   Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer [J].
Bonomi, P .
SEMINARS IN ONCOLOGY, 2002, 29 (01) :78-86
[6]   Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation [J].
Cheng, SF ;
Lovett, DH .
AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (06) :1937-1949
[7]   Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury [J].
Cheng, Sunfa ;
Pollock, Allan S. ;
Mahimkar, Rajeev ;
Olson, Jean L. ;
Lovett, David H. .
FASEB JOURNAL, 2006, 20 (11) :1898-+
[8]   Gelatinase B is diabetogenic in acute and chronic pancreatitis by cleaving insulin [J].
Descamps, FJ ;
Van den Steen, PE ;
Martens, E ;
Ballaux, F ;
Geboes, K ;
Opdenakker, G .
FASEB JOURNAL, 2003, 17 (03) :887-+
[9]   Hypertension, matrix metalloproteinases and target organ damage [J].
Donnelly, R ;
Collinson, DJ ;
Manning, G .
JOURNAL OF HYPERTENSION, 2003, 21 (09) :1627-1630
[10]   Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions [J].
Dubois, B ;
Masure, S ;
Hurtenbach, U ;
Paemen, L ;
Heremans, H ;
van den Oord, J ;
Sciot, R ;
Meinhardt, T ;
Hämmerling, G ;
Opdenakker, G ;
Arnold, B .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (11) :1507-1515
12345